BackMillendo Therapeutics Overview

Millendo Therapeutics Total Current Liabilities

Track Millendo Therapeutics's total current liabilities ($3.3M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$3.31M
74.87% YoYΔ $-9.87M vs prior year quarter

Peer average

Loading

Millendo Therapeutics Total Current Liabilities History

Loading

Millendo Therapeutics vs. peers: Total Current Liabilities Comparison

Loading

Millendo Therapeutics Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Millendo Therapeutics (MLND) FAQ

As of the most recent data (March 2026), MLND shows a total current liabilities of $3.3M. That compares with $13M in the prior-year period — down 74.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, MLND's total current liabilities is now $3.3M (was $13M) — a 74.9% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Millendo Therapeutics is outperforming or lagging.

Tracking MLND's total current liabilities over time shows whether Millendo Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $3.3M That compares with $13M in the prior-year period — down 74.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total current liabilities page, Stockcircle has Millendo Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total current liabilities (currently $3.3M) with ownership activity and broader fundamentals.

Millendo Therapeutics's total current liabilities is $3.3M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.